The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1-Reference-Cited by-同舟云学术

The anti-fibrotic drug pirfenidone inhibits liver fibrosis by targeting the small oxidoreductase glutaredoxin-1

Published:2021-09-03 Issue:36 Volume:7 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Xi Yue¹²^ORCID,Li Yanping³^ORCID,Xu Pengfei¹^ORCID,Li Sihan¹,Liu Zhengsheng⁴,Tung Hung-chun¹^ORCID,Cai Xinran¹^ORCID,Wang Jingyuan¹^ORCID,Huang Haozhe¹,Wang Menglin⁴^ORCID,Xu Meishu¹,Ren Songrong¹^ORCID,Li Song¹^ORCID,Zhang Min¹^ORCID,Lee Yong J.⁵^ORCID,Huang Leaf⁴^ORCID,Yang Da¹^ORCID,He Jinhan³,Huang Zhiying²^ORCID,Xie Wen¹⁶^ORCID

Affiliation:

1. Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA.

2. School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.

3. Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

4. Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.

5. Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15261, USA.

6. Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15261, USA.

Abstract

Pirfenidone inhibits HSC activation and liver fibrosis by targeting glutaredoxin-1 and reducing Smad3 glutathionylation.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference44 articles.

1. Liver fibrosis

2. Liver fibrosis and repair: immune regulation of wound healing in a solid organ

3. Nonalcoholic Steatohepatitis: The Second Leading Indication for Liver Transplantation in the USA